Search

Displaying results 4751 - 4760 of 10000 in total
  1. Drug

    Apricot kernel oil

    go.drugbank.com/drugs/DB14324
    Approved

    Apricot kernel oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Azadirachta indica leaf

    go.drugbank.com/drugs/DB14352
    Approved

    Azadirachta indica leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. … Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity.

  4. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  5. Drug

    KD3010

    go.drugbank.com/drugs/DB05188
    Experimental

    KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.

  6. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  7. Drug

    Tridolgosir

    go.drugbank.com/drugs/DB02034
    Experimental

    An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.

  8. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.

  9. Drug

    Nangibotide

    go.drugbank.com/drugs/DB16247
    Investigational

    Nangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).

  10. Drug

    Ditekiren

    go.drugbank.com/drugs/DB19992
    Experimental

    Ditekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.

    Categories: Agents Acting on the Renin-Angiotensin System